Pharmacokinetics of pegylated interferons: What is misleading?

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 3, 2004, Pages

  Caliceti, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Pegylated interferon; Pharmacokinetics; Volume of distribution

Indexed keywords

ALPHA INTERFERON; INTERFERON; MACROGOL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DISEASE CARRIER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG POTENCY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NEUTROPENIA; PHARMACODYNAMICS; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; VIROLOGY; VIRUS RESISTANCE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 18444405565     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(04)80002-1     Document Type: Article

References (31)

1. Wills R.J. Clinical pharmacokinetics of interferons Pharmacokinet 19 1990 390-399
2. Lutchman G. Hoofnagle J.H. Viral kinetics in hepatitis C Hepatology 37 2003 1257-1259
3. Reddy K.R. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs Ann Pharmacother 34 2000 915-923
4. Alberti A. Benvegnù L. Management of hepatitis C J Hepatol 38 Suppl 1 2003 S104-S118
5. Delgado C. Francis G.E. Fisher D. The uses and properties of PEG-linked proteins Crit Rev Ther Drug Carrier Syst 9 3-4 1992 249-304
6. Luxon B.A. Grace M. Brassard D. Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection Clin Ther 24 2002 1363-1383
7. Abuchowski A. van Es T. Palczuk N.C. Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J Biol Chem 252 1977 3578-3581
8. Harris J.M. Martin N.E. Modi M. Pegylation: A novel process for modifying pharmacokinefcs Clin Pharmacokinet 40 7 2001 539-551
9. Gaertner H.F. Offord R.E. Site-specific attachement of functionalized poly(ethylene glycol) to the amino terminus of proteins Bioconjug Chem 7 1996 38-44
10. Bailon P. Palleroni A. Schaffer C.A. Spence C.L. Fung W.J. Porter J.E. et al. Rational design of a potent, long-lasting form of interferon: A 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for thetreatment of hepatitis C Bioconjug Chem 12 2 2001 195-202
11. Grace M. Youngster S. Gitlin G. Sydor W. Xie L. Westreich L. et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b J Interferon Cytokine Res. 21 12 2001 1103-1115
12. Caliceti P. Veronese F.M. Pharmacokinefc and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv Drug Deliv Rev 55 10 2003 1261-1277
13. Monfardini C. et al. A branched monomethoxypoly(ethylene glycol) for protein modification Bioconjugate Chem 6 1995 62-69
14. Kozlowski A. Harris J.M. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C J Control Release 72 1-3 2001 217-224
15. Glue P. Fang J.W. Rauzier-Panis R. Raffanel C. Sabo R. Gupta S.K. et al. Pegylated interferon-alphalb: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group Clin Pharmacol Ther 68 5 2000 556-567
16. Kozlowski A. Charles S.A. Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C BioDrugs 15 7 2001 419-429
17. Russo M.W. Fried M.W. Side effects of therapy for chronic hepatitis C Gastroenterology 124 6 2003 1711-1719
18. Perry C.M. Jarvis B. Spotlight on peginterferon-alpha-2a (40kD) in chronic hepatitis C BioDrugs 16 3 2002 213-217
19. Mighoresi L. Riva E. Antonelli G. Russo F. Ricci G.L. Localization of hepatitis C virus in gastrointestinal mucosa: A possible reservoir for relapse Hepatology 38 3 2003 775
20. Hu Y. Shahidi A. Park S. Guilfoyle D. Hirshfield I. Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction Am J Clin Pathol 119 1 2003 95-100
21. Carrozzo M. Quadri R. Latorre P. Pentenero M. Paganin S. Bertolusso G. et al. Molecular evidence that the hepatitis C virus replicates in the oral mucosa J Hepatol 37 3 2002 364-369
22. Yan F.M. Chen A.S. Hao F. Zhao X.P. Gu C.H. Zhao L.B. Yang D.L. Hao L.J. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C World J Gastroenterol 6 6 2000 805-811
23. Bailon P. et al. Polyethylene glycol-conjugated pharmaceutical proteins Pharm Sci Tech Today 1 1998 352-356
24. Manns M.P. et al. Peginterferon alpha-2b in combination with ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomised trial Lancet 358 2001 958-965
25. Fried M.W. Shiffman M.L. Reddy K. Smith C. Marino G. Goncales F. et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982
26. Hadziyannis S.J. Sette H. Jr Morgan T.R. Balan V. Diago M. Marcellin P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med. 140 2004 346-355
27. Zeuzem S. Diago M. Gane E. Shiffman M. International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alpha-2a (40kD) (Pegasys) and ribavirin (Copegus) Hepatology 38 Suppl 1 2003 Abstract 106
28. Lamb M.W. Martin N.E. Weight-based versus fixed dosing of peginterferon (40kDa) alpha-2a Ann Pharmacother 36 5 2002 933-935
29. Zeuzem S. Feinman S.V. Rasenack J. Heathcote E.J. Lai M.Y. Gane E. et al. Peginterferon alpha-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666-1672
30. Lee S.S. Heathcote E.J. Reddy K.R. Zeuzem S. Fried M.W. Wright T.L. et al. Prognostic factors and early predictability of sustained response with peginterferon alpha-2a (40kD) J Hepatol 37 2002 500-506
31. FDA analysis of the Fried and Hadziyannis study. FDAbriefing document. http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3909B1_02_FDA%20briefing%20%package%20.doc.